DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Emcure Pharmaceuticals Limited — Analyst/Investor Meet Para A-XBRL

NSE 1 hr ago·14 Oct 2026, 11:23 am

Emcure Pharmaceuticals

Emcure Pharmaceuticals has informed stock exchanges that it is scheduled to hold an analyst or institutional investor meeting. This disclosure is made in compliance with Para A-XBRL, a regulatory requirement for listed companies to proactively communicate with the market about upcoming interactions with financial experts.

For investors, this meeting is significant as it provides a platform for the company's management to discuss its future strategy, operational performance, and upcoming projects directly with the financial community. It offers a chance to clarify doubts and gauge the sentiment of the market regarding the firm's growth trajectory.

Investors should watch for any specific updates on product pipelines, expansion plans, or guidance given during the session. This information can be crucial for assessing the company's near-term prospects and making informed investment decisions.